Effects of Fluoxetine Treatment on Striatal Dopamine Transporter Binding and Cerebrospinal Fluid Insulin-Like Growth Factor-1 in Children with Autism
| Autor: | I. Makkonen, J. Kuikka, H. Kokki, Raili Riikonen, Ursula Turpeinen |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty Adolescent medicine.medical_treatment Neuroprotection Insulin-like growth factor Cerebrospinal fluid Fluoxetine Internal medicine medicine Humans Autistic Disorder Insulin-Like Growth Factor I Child Dopamine transporter Tomography Emission-Computed Single-Photon Dopamine Plasma Membrane Transport Proteins biology business.industry Neurotoxicity Transporter General Medicine medicine.disease Corpus Striatum Endocrinology Child Preschool Pediatrics Perinatology and Child Health biology.protein Autism Female Neurology (clinical) business Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | Neuropediatrics. 42:207-209 |
| ISSN: | 1439-1899 0174-304X |
| DOI: | 10.1055/s-0031-1291242 |
| Popis: | A positive effect of fluoxetine has been shown in some children with autism. The present study was undertaken to correlate striatal dopamine transporter (DAT) binding and cerebrospinal fluid insulin-like growth factor-1 (CSF-IGF-1) with clinical response in autistic children (n=13, age 5-16 years) after a 6-month fluoxetine treatment. Good clinical responders (n=6) had a decrease (p=0.031) in DAT binding as assessed using single-photon emission computed tomography with [123I]-nor-β-CIT, whereas poor responders had a trend to an increase. An increase in CSF-IGF-1 (p=0.003) was detected after the treatment period, but no correlation between the clinical response and CSF-IGF-1 was found. In conclusion, fluoxetine decreases DAT binding indicating alleviation of the hyperdopaminergic state and increases CSF-IGF-1 concentration, which may also have a neuroprotective effect against dopamine-induced neurotoxicity in autistic children. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|